These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2457560)

  • 1. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis.
    Sica DA; Yonce C; Small R; Cefali E; Harford A; Poynor W
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):59-64. PubMed ID: 2457560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].
    Gawrońska-Szklarz B; Górnik W; Kutrzeba J; Wójcicki J; Zakrzewski J
    Pol Tyg Lek; 1992 Oct 5-12; 47(40-41):921-3. PubMed ID: 1284448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Raehl CL; Moorthy AV; Beirne GJ
    Nephron; 1986; 44(3):191-4. PubMed ID: 2431330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
    Kroboth PD; Mitchum K; Puschett JB
    Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations.
    Bauer LA; Black D; Gensler A; Sprinkle J
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):213-6. PubMed ID: 2472362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose dependent effect of cimetidine on procainamide disposition in man.
    Lai MY; Jiang FM; Chung CH; Chen HC; Chao PD
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):118-21. PubMed ID: 2457561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide.
    Atkinson AJ; Ruo TI; Piergies AA
    Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Simultaneous predictions of disposition kinetics of procainamide and its metabolite N-acetylprocainamide in rat by a physiological pharmacokinetic model].
    Liu XD; Deng N; Huang SK
    Yao Xue Xue Bao; 1991; 26(10):725-32. PubMed ID: 1726674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration.
    Ellis EJ; Ravis WR; Malloy M; Duran SH; Smyth BG
    J Vet Pharmacol Ther; 1994 Aug; 17(4):265-70. PubMed ID: 7525982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen with that into the peritoneal cavity in rats.
    Arimori K; Hashimoto Y; Nakano M
    Chem Pharm Bull (Tokyo); 1990 Jul; 38(7):2050-2. PubMed ID: 1702691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of very rapid emit Qst methods for measuring serum procainamide and N-acetylprocainamide concentrations.
    Carnes CA; Coyle JD
    Pharmacotherapy; 1992; 12(1):40-4. PubMed ID: 1372425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of amiodarone on kinetics of procainamide and its major metabolite disposition in rabbit].
    Liu XQ; Huang SK
    Zhongguo Yao Li Xue Bao; 1992 Sep; 13(5):454-6. PubMed ID: 1284402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longer plasma half-life for procainamide utilizing a very sensitive high performance liquid chromatography assay.
    Jamali F; Alballa RS; Mehvar R; Lemko CH
    Ther Drug Monit; 1988; 10(1):91-6. PubMed ID: 2453956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity.
    Low CL; Phelps KR; Bailie GR
    Nephrol Dial Transplant; 1996 May; 11(5):881-4. PubMed ID: 8671917
    [No Abstract]   [Full Text] [Related]  

  • 16. Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure.
    Arimori K; Nakano M
    J Pharmacobiodyn; 1988 Jul; 11(7):504-11. PubMed ID: 2460613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis.
    Bouchet JL; Albin H; Quentin C; de Barbeyrac B; Vinçon G; Martin-Dupont P; Potaux L; Aparicio M
    Clin Nephrol; 1988 Jan; 29(1):35-40. PubMed ID: 3383462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite].
    Liu XQ; Huang SK
    Zhongguo Yao Li Xue Bao; 1991 Jan; 12(1):7-11. PubMed ID: 1719744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Acetylprocainamide levels in patients with end-stage renal failure.
    Gibson TP; Matusik EJ; Briggs WA
    Clin Pharmacol Ther; 1976 Feb; 19(2):206-12. PubMed ID: 1261157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.